Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
ChemoCentryx Stock Price (Quote) NASDAQ:CCXI
$34.57 ( -1.26% ) Friday, 22nd Oct 2021
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $16.75 | $42.16 | Friday, 22nd Oct 2021 CCXI stock ended at $34.57. This is 1.26% less than the trading day before Thursday, 21st Oct 2021. During the day the stock fluctuated 6.83% from a day low at $33.55 to a day high of $35.84. |
| 90 days | $13.11 | $42.16 | |
| 52 weeks | $9.53 | $70.29 |
Historical ChemoCentryx prices
| Date | Open | High | Low | Close | Volume |
| 2021-10-22 | $34.29 | $35.84 | $33.55 | $34.57 | 1 997 106 |
| 2021-10-21 | $34.70 | $36.01 | $34.59 | $35.01 | 1 435 942 |
| 2021-10-20 | $33.60 | $35.64 | $33.55 | $34.85 | 1 925 381 |
| 2021-10-19 | $32.55 | $34.47 | $31.77 | $33.65 | 2 499 161 |
| 2021-10-18 | $34.64 | $34.86 | $31.72 | $32.43 | 4 985 245 |
| 2021-10-15 | $36.53 | $36.91 | $34.37 | $34.47 | 3 823 650 |
| 2021-10-14 | $37.40 | $38.49 | $36.43 | $37.08 | 3 592 859 |
| 2021-10-13 | $35.50 | $37.22 | $34.61 | $36.91 | 3 893 571 |
| 2021-10-12 | $40.22 | $41.97 | $34.74 | $36.00 | 15 514 039 |
| 2021-10-11 | $37.85 | $42.16 | $36.55 | $40.50 | 37 194 991 |
| 2021-10-08 | $36.98 | $40.90 | $29.07 | $38.41 | 144 512 945 |
| 2021-10-07 | $18.61 | $21.31 | $17.14 | $19.60 | 5 664 290 |
| 2021-10-06 | $18.80 | $19.93 | $18.12 | $18.59 | 2 199 014 |
| 2021-10-05 | $18.65 | $19.89 | $18.39 | $19.00 | 2 419 792 |
| 2021-10-04 | $18.32 | $19.07 | $18.14 | $18.51 | 1 839 400 |
| 2021-10-01 | $17.36 | $18.65 | $17.13 | $18.38 | 2 160 014 |
| 2021-09-30 | $19.23 | $19.23 | $16.75 | $17.10 | 3 806 819 |
| 2021-09-29 | $20.03 | $20.55 | $19.52 | $19.56 | 2 363 886 |
| 2021-09-28 | $19.50 | $20.60 | $18.90 | $19.83 | 3 828 902 |
| 2021-09-27 | $18.96 | $19.68 | $18.35 | $19.21 | 3 646 742 |
| 2021-09-24 | $18.03 | $18.41 | $17.72 | $18.20 | 2 131 877 |
| 2021-09-23 | $17.21 | $18.03 | $17.13 | $17.97 | 1 448 789 |
| 2021-09-22 | $17.08 | $17.29 | $16.76 | $17.19 | 1 375 519 |
| 2021-09-21 | $16.50 | $17.20 | $16.48 | $17.08 | 1 153 344 |
| 2021-09-20 | $16.08 | $17.33 | $16.02 | $16.48 | 1 760 589 |
| 2021-09-17 | $16.00 | $16.75 | $15.81 | $16.57 | 2 025 808 |
| 2021-09-16 | $15.81 | $16.11 | $15.56 | $15.99 | 915 594 |
| 2021-09-15 | $15.65 | $16.13 | $15.55 | $15.98 | 802 465 |
| 2021-09-14 | $15.90 | $16.07 | $15.35 | $15.67 | 1 051 495 |
| 2021-09-13 | $15.50 | $16.37 | $15.15 | $15.91 | 1 351 412 |
| 2021-09-10 | $15.98 | $16.08 | $15.37 | $15.42 | 916 973 |
| 2021-09-09 | $15.86 | $16.25 | $15.61 | $15.99 | 1 102 743 |
| 2021-09-08 | $15.84 | $16.36 | $15.52 | $15.91 | 1 530 352 |
| 2021-09-07 | $15.91 | $16.28 | $15.48 | $15.81 | 1 032 163 |
| 2021-09-03 | $16.25 | $16.28 | $15.80 | $15.92 | 905 902 |
| 2021-09-02 | $16.39 | $16.39 | $15.84 | $16.21 | 776 920 |
| 2021-09-01 | $15.81 | $16.48 | $15.72 | $16.29 | 1 492 670 |
| 2021-08-31 | $15.64 | $16.12 | $15.58 | $15.81 | 925 472 |
| 2021-08-30 | $15.65 | $15.93 | $15.13 | $15.43 | 855 281 |
| 2021-08-27 | $15.40 | $16.18 | $15.26 | $15.73 | 1 359 033 |
| 2021-08-26 | $15.14 | $15.76 | $15.06 | $15.46 | 1 179 418 |
| 2021-08-25 | $14.80 | $15.45 | $14.55 | $15.16 | 940 251 |
| 2021-08-24 | $14.74 | $14.89 | $14.35 | $14.88 | 819 594 |
| 2021-08-23 | $14.28 | $14.94 | $14.24 | $14.72 | 1 265 290 |
| 2021-08-20 | $13.71 | $14.48 | $13.67 | $14.18 | 878 467 |
| 2021-08-19 | $13.70 | $14.10 | $13.41 | $13.69 | 1 638 435 |
| 2021-08-18 | $13.80 | $14.29 | $13.53 | $13.86 | 1 283 833 |
| 2021-08-17 | $13.40 | $13.70 | $13.11 | $13.68 | 1 224 334 |
| 2021-08-16 | $13.96 | $13.96 | $13.46 | $13.53 | 1 159 895 |
| 2021-08-13 | $14.21 | $14.45 | $13.87 | $14.00 | 1 035 599 |
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders, and cancer in the United States. Its lead drug candidates in clinical development include CCX168, which is in Phase II clinical trials for the treatment of orphan and rare diseases; CCX872, which is in Phase I... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Join 95.000+ Happy Subscribers
Don't miss out on the runners!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
